Trials / Terminated
TerminatedNCT01270906
Safety of CHIR-258 (TKI258) in Advanced Solid Tumors
A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I dose finding study in solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHIR-258 (TKI258) |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-10-01
- First posted
- 2011-01-05
- Last updated
- 2011-01-05
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01270906. Inclusion in this directory is not an endorsement.